Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page & `6 r$ Z9 f+ Q5 |1 E% m6 Y/ f n( `
) n f4 V1 m' I$ c
6 @# V- Y% Q6 j$ r8 l( [' o+ {
Sub-category:8 Y% ~2 k: `# P2 [- q* B9 M$ z
Molecular Targets
3 [2 U _ E8 N- ` \
( }+ ^4 j" y& w3 S# F6 `* p) h: o& f. U
Category:$ v5 a1 e9 E. E* P; j
Tumor Biology
5 e& T L& ^4 Y2 g5 m* `3 p
: h4 r, U; {# _7 B% p' j! c# D4 _1 O2 f6 k' a( w
Meeting:
0 f- J0 L& l- f! g' y; E2 {2011 ASCO Annual Meeting
: G$ s+ X) g9 O
' R9 G3 |" J x. c7 t
/ c8 \: s7 o* E3 P; MSession Type and Session Title:
: ]8 W7 q7 c: E- L' FPoster Discussion Session, Tumor Biology
( t: G; q, }6 O4 Z! e7 h6 Z5 l
) t% [7 E" _+ Q% F
1 L. G) b# Z, C( \0 ~* PAbstract No:4 p; F! O5 j2 E
10517
, p& J- G' I$ o$ ~$ c) A u/ Q3 P7 K
: l; v/ e: P5 `& q$ W' E) @
Citation:
# ]0 S( j x( O8 NJ Clin Oncol 29: 2011 (suppl; abstr 10517)
. ^/ W( v1 P2 @ m: w0 l* U* W$ ~, q' v. ?! D; ~9 I
' s% ~0 d y% P5 x8 l0 CAuthor(s):
9 [; Y/ f/ ~; \% JJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
0 _$ e2 }6 y+ Q$ G7 ^1 a: m. f& J
: J0 `) ?% A7 D; \. E
, Z, P1 e, S8 z2 d4 N! vAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
3 X; Q+ m Z- }* f5 f5 d4 z$ S' [/ u/ C# v# N! Y n. A( i
Abstract Disclosures
% @$ ^1 F* X2 W a. I- L# H; |. \* b* S! T3 v, B1 d
Abstract:
+ `: n/ t7 }9 z0 f5 A1 i, s& E+ {* I1 H1 q5 }0 ]
' b- S9 P" P9 z
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
5 l" K6 ~$ F; q: X6 e
1 m) D3 x5 L K2 N5 c
9 h6 M. i$ M* p5 a( ~5 S5 K |
显身卡
